A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan
NCT ID: NCT00503477
Last Updated: 2009-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
40 participants
INTERVENTIONAL
2005-10-31
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients
NCT00613652
AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours
NCT00704366
Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies
NCT02398747
Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
NCT01213160
Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies
NCT01353781
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD2171
oral tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* life expectancy is 12 weeks or longer
Exclusion Criteria
* patient with inappropriate laboratory test values
* patient with poorly controlled hypertension
20 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jane Robertson
Role: STUDY_DIRECTOR
AstraZeneca
Tomohide Tamura, MD
Role: PRINCIPAL_INVESTIGATOR
National Cancer Centre Hospital, Tokyo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Shizuoka, , Japan
Research Site
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D8480C00023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.